ExamFinch.com My Study

Study guide

9.2 Potassium, Calcium, Magnesium & Phosphate Disorders

Practice this exam

ABIM Critical Care Medicine Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Orientation: Format, Blueprint & Study Strategy

1.1 ABIM Critical Care Medicine Exam: Format, Blueprint & Study Strategy

2 Chapter 2: Acute Respiratory Failure & ARDS

2.1 ARDS Definition, Pathophysiology & Phenotypes 2.2 Lung-Protective Mechanical Ventilation 2.3 Refractory ARDS: Prone Positioning, Neuromuscular Blockade & VV-ECMO

3 Chapter 3: Obstructive Airways, Pulmonary Vascular & Pleural Emergencies

3.1 Severe Asthma & COPD Exacerbations in the ICU 3.2 Massive & Submassive Pulmonary Embolism 3.3 Pulmonary Hypertension & Right Ventricular Failure in the ICU 3.4 Massive Hemoptysis, Complex Pleural Effusions & Thoracic Drainage

4 Chapter 4: Airway, Parenchymal & Nonthrombotic Pulmonary Emergencies

4.1 Airway Management, Upper-Airway Obstruction & Artificial-Airway Complications 4.2 Diffuse Alveolar Hemorrhage, Interstitial Lung Disease, Pulmonary Vasculitis & Noncardiogenic Edema 4.3 Severe Community-Acquired & Viral Pneumonia 4.4 Nonthrombotic Embolism (Air, Fat, Amniotic Fluid, Tumor, Septic) & Acute Chest Syndrome

5 Chapter 5: Mechanical Ventilation Modes, Dyssynchrony & Liberation

5.1 Mechanical Ventilator Modes & Advanced Breath Delivery 5.2 Patient-Ventilator Dyssynchrony & Waveform Analysis 5.3 Ventilator Liberation, Spontaneous Breathing Trials & Post-Extubation Support

6 Chapter 6: Shock Syndromes & Hemodynamic Principles

6.1 Shock Classification, Cellular Pathophysiology & Biomarkers 6.2 Hemodynamic Monitoring: Arterial Lines, CVP & Pulmonary Artery Catheter 6.3 Dynamic Assessment of Fluid Responsiveness & Resuscitation Targets

7 Chapter 7: Vasoactive Therapies & Mechanical Circulatory Support

7.1 Vasopressors & Inotropes: Pharmacology & Clinical Titration 7.2 Temporary Mechanical Circulatory Support: IABP, Impella & TandemHeart 7.3 Venoarterial ECMO (VA-ECMO) & Differential Hypoxemia 7.4 Post-Cardiac Arrest Care, Targeted Temperature Management & Neuroprognostication

8 Chapter 8: Acute Kidney Injury & Renal Replacement Therapy

8.1 KDIGO AKI Classification, Etiologies & Diagnostic Evaluation 8.2 Continuous Renal Replacement Therapy (CRRT) vs Intermittent Hemodialysis 8.3 Indications & Timing for RRT in Critical Illness: AKIKI & STARRT-AKI

9 Chapter 9: Electrolyte, Acid-Base & Endocrine Emergencies

9.1 Severe Dysnatremias: Hyponatremia, Hypernatremia & Osmotic Demyelination 9.2 Potassium, Calcium, Magnesium & Phosphate Disorders 9.3 Complex & Mixed Acid-Base Disorders: Boston vs Copenhagen vs Stewart 9.4 Endocrine Crises: DKA, HHS, Thyroid Storm, Myxedema Coma & Adrenal Crisis

10 Chapter 10: Glycemic Control, Hyperammonemia, Pituitary & Adrenal Disorders

10.1 ICU Glycemic Control & Severe Hypoglycemia 10.2 Non-Hepatic Hyperammonemia & Metabolic Encephalopathy 10.3 Pituitary Emergencies, Adrenal Excess & Critical Illness-Related Corticosteroid Insufficiency

11 Chapter 11: Acute Coronary Syndromes & Cardiac Arrhythmias

11.1 Acute Coronary Syndromes & Mechanical Complications of Myocardial Infarction 11.2 Critical Tachyarrhythmias: Atrial Fibrillation with RVR, VT & VF 11.3 Critical Bradyarrhythmias, Conduction Blocks & Temporary Cardiac Pacing

12 Chapter 12: Acute Heart Failure, Valvular & Pericardial Emergencies

12.1 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 12.2 Acute Valvular Regurgitation & Prosthetic Valve Emergencies 12.3 Pericardial Tamponade & Acute Aortic Syndromes

13 Chapter 13: Myocardial Disease, Hypertensive & Cardiac Device Emergencies

13.1 Fulminant Myocarditis, Stress & Peripartum Cardiomyopathy, and Hypertrophic Cardiomyopathy 13.2 Hypertensive Emergencies & Ruptured Abdominal Aortic Aneurysm 13.3 Implanted Cardiac Devices, LVAD Emergencies & Electrical Storm

14 Chapter 14: Sepsis & Systemic Infectious Diseases

14.1 Sepsis-3 Definitions & Surviving Sepsis Campaign 2026 Guidelines 14.2 Refractory Septic Shock & Adjunctive Therapies 14.3 Multidrug-Resistant Pathogens & Antimicrobial Stewardship in the ICU

15 Chapter 15: ICU-Acquired & Severe Focal Infections

15.1 Hospital-Acquired & Ventilator-Associated Pneumonia 15.2 Central Line-Associated Bloodstream Infections & Catheter-Associated UTIs 15.3 Intra-Abdominal Sepsis, Necrotizing Soft Tissue Infections & CNS Infections

16 Chapter 16: Focal, Special-Host & Systemic Infections

16.1 CNS Infections Beyond Bacterial Meningitis: Encephalitis, Brain Abscess & Epidural Abscess 16.2 Infections in the Immunocompromised Host, Tropical & Bioterror Infections 16.3 Infective Endocarditis, Device Infections & Other Focal Cardiovascular Infections 16.4 Antimicrobial Pharmacokinetics, Allergy, Toxicity & Infection Prevention 16.5 Gastrointestinal & Hepatobiliary Infections: Fulminant C. difficile, Typhlitis, CMV Colitis & Abscesses

17 Chapter 17: Neurocritical Care & Coma

17.1 Coma, Altered Mental Status & Acute Delirium in the ICU 17.2 Status Epilepticus & Non-Convulsive Status Epilepticus 17.3 Acute Ischemic Stroke & Intracranial Hemorrhage

18 Chapter 18: Cerebrovascular Syndromes, Encephalopathy & Withdrawal States

18.1 Cerebral Venous Sinus Thrombosis, PRES & Reversible Cerebral Vasoconstriction Syndrome 18.2 Alcohol & Sedative Withdrawal, Wernicke Encephalopathy & Drug-Induced Encephalopathy

19 Chapter 19: Intracranial Hypertension & Neuromuscular Weakness

19.1 Intracranial Pressure Monitoring, Cerebral Perfusion & Tiered ICP Management 19.2 Acute Neuromuscular Respiratory Failure, ICU-Acquired Weakness & Brain Death Determination

20 Chapter 20: Traumatic Brain Injury, Spinal Cord Injury & Toxin-Mediated Paralysis

20.1 Traumatic Brain Injury Management & Paroxysmal Sympathetic Hyperactivity 20.2 Acute Spinal Cord Injury, Neurogenic Shock & Autonomic Dysreflexia 20.3 Toxin-Mediated Paralysis & Neuromuscular Crises: Botulism, Tetanus, Tick Paralysis & Myasthenic Crisis

21 Chapter 21: Gastrointestinal, Hepatic & Abdominal Emergencies

21.1 Acute Upper & Lower Gastrointestinal Bleeding in the ICU 21.2 Acute Liver Failure & Severe Acute Pancreatitis 21.3 Abdominal Compartment Syndrome & Acute Mesenteric Ischemia

22 Chapter 22: Luminal GI Emergencies & Complications of Cirrhosis

22.1 Esophageal, Gastric & Bowel Emergencies: Perforation, Obstruction, Ogilvie Syndrome & Colonic Ischemia 22.2 Complications of Cirrhosis: Alcohol-Associated Hepatitis, Hepatorenal Syndrome & Pulmonary Vascular Syndromes

23 Chapter 23: Trauma, Burns & Perioperative Critical Care

23.1 Polytrauma Resuscitation, Damage Control & Massive Transfusion 23.2 Severe Burn Injury, Inhalation Injury & Environmental Emergencies 23.3 Perioperative Critical Care for High-Risk Surgical Patients

24 Chapter 24: Thoracic Trauma, Environmental Injury & Obstetric Critical Care

24.1 Thoracic Trauma: Flail Chest, Pulmonary Contusion, Great Vessel & Tracheobronchial Injury 24.2 Environmental Injury: Drowning, Diving, Altitude, Heat, Cold, Electrical & Radiation 24.3 Obstetric & Genitourinary Emergencies and the Physiology of Pregnancy

25 Chapter 25: Transplantation, Donor Management & Post-Cardiac Surgery Care

25.1 Solid Organ Transplant Recipients & Deceased Donor Management 25.2 Post-Cardiac Surgery Critical Care: Bleeding, Tamponade, Low Output & Vasoplegia

26 Chapter 26: Hematologic Emergencies, Toxicology, Critical Ultrasound & ICU Liberation

26.1 Hematologic Emergencies in the ICU: HIT, DIC, TMA & Anticoagulant Reversal 26.2 Critical Care Toxicology, Toxidromes & Specific Antidotes 26.3 Critical Care Point-of-Care Ultrasound (POCUS) 26.4 ICU Liberation, Analgosedation, Goals of Care & Critical Care Ethics

27 Chapter 27: Transfusion Medicine, Hematologic & Oncologic Disorders

27.1 Transfusion Medicine: Products, Thresholds, Reactions & Apheresis 27.2 Red and White Cell Disorders, Hemoglobinopathies, Factor Deficiencies & Hypercoagulable States 27.3 Oncologic Emergencies, Hematopoietic Cell Transplant Complications & Cellular Therapy Toxicity

28 Chapter 28: Clinical Pharmacology, Adverse Drug Reactions & Specific Poisonings

28.1 Pharmacokinetic Principles, Dose Adjustment & Drug Interactions in Critical Illness 28.2 Adverse Drug Reactions: Anaphylaxis, Severe Cutaneous Reactions & Hyperthermic Syndromes 28.3 Specific Poisonings: Sodium-Channel Blockers, Lithium, Valproate, Theophylline, Iron, Sulfonylureas & Methemoglobinemia

29 Chapter 29: Ethics, Research Methods, Administration & Abdominal Ultrasound

29.1 Advance Care Planning, Nonbeneficial Treatment, Informed Consent & Confidentiality 29.2 Critical Care Research Methods, Statistics, IRB Oversight & Quality Improvement 29.3 Abdominal, Vascular & Procedural Point-of-Care Ultrasound

9.2 Potassium, Calcium, Magnesium & Phosphate Disorders

Key Takeaways Explain This Topic AI

Severe hyperkalemia ( K > 6.5 mEq/L K > 6.5\text{ mEq/L} K > 6.5 mEq/L or ECG changes) mandates immediate sequenced therapy: myocardial membrane stabilization with IV calcium, rapid intracellular shifting (regular insulin with dextrose, nebulized albuterol), and definitive elimination (loop diuretics, potassium binders, or emergent hemodialysis).

Intravenous calcium chloride delivers three times the elemental calcium concentration of calcium gluconate and is the agent of choice in cardiac arrest, profound shock, or imminent sine-wave degeneration.

Refractory hypokalemia cannot be corrected until concurrent hypomagnesemia is identified and repleted, as intracellular magnesium is required to inhibit the ROMK channels in the cortical collecting duct.

Severe hypercalcemia crisis ( > 14 mg/dL > 14\text{ mg/dL} > 14 mg/dL ) requires aggressive isotonic saline hydration, subcutaneous calcitonin for rapid early reduction, and bisphosphonates (zoledronic acid) or denosumab, with hemodialysis reserved for renal or cardiac failure.

Tumor Lysis Syndrome (Cairo-Bishop criteria) requires aggressive hydration, recombinant urate oxidase (rasburicase), and strict avoidance of empiric calcium replacement for asymptomatic hypocalcemia to prevent lethal metastatic calcium phosphate precipitation.

Last updated: October 2026

Severe Hyperkalemia: Pathophysiology and Electrocardiographic Cascade

Potassium is the predominant intracellular cation ( 140 − 150 mEq/L 140-150\text{ mEq/L} 140 − 150 mEq/L intracellularly vs. 3.5 − 5.0 mEq/L 3.5-5.0\text{ mEq/L} 3.5 − 5.0 mEq/L extracellularly). The resting membrane potential ( V m V_m V m ​ ) of cardiac myocytes is determined by the ratio of intracellular to extracellular potassium concentration, as defined by the Nernst equation:

V m ≈ − 61.5 × log ⁡ 10 ( [ K + ] in [ K + ] out ) V_m \approx -61.5 \times \log_{10}\left(\frac{[\text{K}^+]_{\text{in}}}{[\text{K}^+]_{\text{out}}}\right) V m ​ ≈ − 61.5 × lo g 10 ​ ( [ K + ] out ​ [ K + ] in ​ ​ )

As extracellular potassium rises, the resting membrane potential becomes less negative (partially depolarized, shifting from − 90 mV -90\text{ mV} − 90 mV toward − 70 mV -70\text{ mV} − 70 mV ). While closer to threshold potential, this persistent baseline depolarization paradoxically inactivates fast voltage-gated sodium channels , depressing Phase 0 cardiac depolarization velocity, slowing intraventricular conduction, and disrupting normal repolarization.

The Electrocardiographic Cascade

The ECG manifestations of hyperkalemia follow a classically progressive, sequential morphology:

Peaked T Waves ( K ≈ 5.5 − 6.5 mEq/L K \approx 5.5-6.5\text{ mEq/L} K ≈ 5.5 − 6.5 mEq/L ) : Narrow-based, tall, symmetric, "tented" T waves, most prominent in precordial leads (V2-V4), reflecting accelerated Phase 3 repolarization via an enhanced rapid delayed rectifier potassium current ( I Kr I_{\text{Kr}} I Kr ​ ), whose conductance rises with extracellular potassium.

Conduction Delays ( K ≈ 6.5 − 7.5 mEq/L K \approx 6.5-7.5\text{ mEq/L} K ≈ 6.5 − 7.5 mEq/L ) : Prolongation of the PR interval, flattening and eventual disappearance of P waves (sinoatrial arrest with junctional escape rhythms), and ST-segment depression.

QRS Complex Widening ( K ≈ 7.0 − 8.0 mEq/L K \approx 7.0-8.0\text{ mEq/L} K ≈ 7.0 − 8.0 mEq/L ) : Diffuse, non-specific intraventricular conduction delay; QRS widens symmetrically and merges with the T wave.

Sine-Wave Pattern ( K > 8.0 − 9.0 mEq/L K > 8.0-9.0\text{ mEq/L} K > 8.0 − 9.0 mEq/L ) : Complete fusion of the widened QRS complex and the T wave into a smooth, sinusoidal undulating waveform. This is a pre-terminal rhythm indicating imminent degenerating ventricular fibrillation, pulseless electrical activity (PEA), or asystole.

Loading diagram...

Warning

Although the electrocardiographic cascade is classic, up to 50% of patients with severe hyperkalemia ( K > 6.5 mEq/L K > 6.5\text{ mEq/L} K > 6.5 mEq/L ) demonstrate no advanced ECG changes prior to sudden cardiovascular collapse. An initial normal ECG must never delay emergent therapy in confirmed severe hyperkalemia.

Three-Phase Emergency Management of Hyperkalemia

Emergency treatment of severe hyperkalemia follows a structured three-phase hierarchy:

Loading diagram...

Comprehensive Hyperkalemia Pharmacotherapy Protocol

Phase Intervention Dose / Route Mechanism Onset / Duration Clinical Nuances & Caveats

Phase 1: Membrane Stabilization Calcium Chloride 10% 10 mL 10\text{ mL} 10 mL ( 1 g 1\text{ g} 1 g ) IV over 2-5 min Antagonizes membrane excitability by raising threshold potential ( V th V_{\text{th}} V th ​ ) Onset: 1 − 3 min 1-3\text{ min} 1 − 3 min ; Duration: 30 − 60 min 30-60\text{ min} 30 − 60 min Delivers 270 mg 270\text{ mg} 270 mg ( 13.6 mEq 13.6\text{ mEq} 13.6 mEq ) elemental calcium ( 3 × 3\times 3 × gluconate). Agent of choice in cardiac arrest, shock, or sine wave. Must infuse via central line if possible; peripheral extravasation causes severe tissue necrosis.

Phase 1: Membrane Stabilization Calcium Gluconate 10% 10 mL 10\text{ mL} 10 mL ( 1 g 1\text{ g} 1 g ) IV over 5-10 min Antagonizes membrane excitability by raising threshold potential Onset: 1 − 3 min 1-3\text{ min} 1 − 3 min ; Duration: 30 − 60 min 30-60\text{ min} 30 − 60 min Delivers 93 mg 93\text{ mg} 93 mg ( 4.65 mEq 4.65\text{ mEq} 4.65 mEq ) elemental calcium. Preferred for peripheral intravenous administration due to lower risk of thrombophlebitis and necrosis. Repeat in 5-10 min if ECG changes persist.

Phase 2: Intracellular Shifting Regular Insulin + Dextrose 10 Units 10\text{ Units} 10 Units Regular Insulin IV bolus + 25 − 50 g 25-50\text{ g} 25 − 50 g D50W ( 50 − 100 mL 50-100\text{ mL} 50 − 100 mL ) Stimulates Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump activity in skeletal muscle Onset: 15 − 30 min 15-30\text{ min} 15 − 30 min ; Duration: 4 − 6 hours 4-6\text{ hours} 4 − 6 hours Lowers serum K K K by 0.5 to 1.2 mEq/L 0.5\text{ to }1.2\text{ mEq/L} 0.5 to 1.2 mEq/L . If baseline glucose > 250 mg/dL > 250\text{ mg/dL} > 250 mg/dL , dextrose may be withheld initially. Monitor blood glucose hourly for up to 6 hours; delayed hypoglycemia occurs in > 15 − 20 % > 15-20\% > 15 − 20% of patients.

Phase 2: Intracellular Shifting Nebulized Albuterol 10 to 20 mg 10\text{ to }20\text{ mg} 10 to 20 mg in 4 mL 4\text{ mL} 4 mL normal saline via continuous nebulizer Beta-2 adrenergic receptor stimulation activates adenylate cyclase and Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase Onset: 20 − 30 min 20-30\text{ min} 20 − 30 min ; Duration: 2 − 4 hours 2-4\text{ hours} 2 − 4 hours Requires 4 to 8 times the standard bronchodilator dose ( 10 − 20 mg 10-20\text{ mg} 10 − 20 mg vs standard 2.5 mg 2.5\text{ mg} 2.5 mg ). Additive effect when combined with insulin. Ineffective in up to 30% of patients receiving chronic beta-blocker therapy.

Phase 2: Intracellular Shifting Sodium Bicarbonate 50 to 100 mEq 50\text{ to }100\text{ mEq} 50 to 100 mEq ( 1 − 2 ampules 1-2\text{ ampules} 1 − 2 ampules ) IV infusion over 10-20 min Raises extracellular pH, stimulating H + / K + \text{H}^+/\text{K}^+ H + / K + exchange Onset: 30 − 60 min 30-60\text{ min} 30 − 60 min ; Duration: 2 − 4 hours 2-4\text{ hours} 2 − 4 hours Ineffective as monotherapy in the absence of metabolic acidosis. Indicated only when severe concurrent metabolic acidosis is present (arterial pH < 7.15 − 7.20 , [ HCO 3 − ] < 12 mEq/L \text{pH} < 7.15-7.20, [\text{HCO}_3^-] < 12\text{ mEq/L} pH < 7.15 − 7.20 , [ HCO 3 − ​ ] < 12 mEq/L ). May precipitate hypocalcemia by increasing calcium-albumin binding.

Phase 3: Potassium Removal Loop Diuretics Furosemide 40 to 80 mg 40\text{ to }80\text{ mg} 40 to 80 mg IV (or bumetanide 1 − 2 mg 1-2\text{ mg} 1 − 2 mg ) Inhibits Na + − K + − 2 Cl − \text{Na}^+-\text{K}^+-2\text{Cl}^- Na + − K + − 2 Cl − co-transporter in thick ascending limb, enhancing distal K excretion Onset: 15 − 30 min 15-30\text{ min} 15 − 30 min ; Duration: 4 − 6 hours 4-6\text{ hours} 4 − 6 hours Requires functional renal tubular reserve (ineffective in oliguric/anuric AKI or advanced ESRD). Monitor for intravascular volume depletion.

Phase 3: Potassium Removal Sodium Zirconium Cyclosilicate (Lokelma) 10 g 10\text{ g} 10 g PO three times daily Inorganic cation exchanger that selectively traps K + K^+ K + in exchange for Na + \text{Na}^+ Na + throughout GI tract Onset: 1 − 2 hours 1-2\text{ hours} 1 − 2 hours ; Duration: 24 hours 24\text{ hours} 24 hours Faster onset than older binders. Does not cause bowel necrosis. Contains 400 mg 400\text{ mg} 400 mg sodium per 5 g 5\text{ g} 5 g dose; monitor for sodium retention/fluid overload in heart failure and ESRD.

Phase 3: Potassium Removal Patiromer (Veltassa) 8.4 g 8.4\text{ g} 8.4 g PO once daily Non-absorbed polymer that binds K + K^+ K + in exchange for calcium in colon Onset: 4 − 7 hours 4-7\text{ hours} 4 − 7 hours ; Duration: 24 hours 24\text{ hours} 24 hours Delayed onset makes it unsuitable for acute emergent reduction; useful for subacute and maintenance management.

Phase 3: Potassium Removal Emergent Hemodialysis Intermittent Hemodialysis via dual-lumen dialysis catheter Direct diffusion across dialyzer membrane against a low-potassium dialysate ( 1 − 2 mEq/L 1-2\text{ mEq/L} 1 − 2 mEq/L ) Immediate on initiation The gold standard definitive therapy. Clears 25 to 50 mEq 25\text{ to }50\text{ mEq} 25 to 50 mEq of potassium per hour. Indicated in refractory hyperkalemia, severe oliguric AKI, ESRD, or ongoing massive tissue breakdown (crush injury, TLS).

Caution

Avoid Sodium Polystyrene Sulfonate (Kayexalate) in critically ill ICU patients. Kayexalate has a delayed, unpredictable onset (hours to days) and its FDA labeling warns of intestinal necrosis, ischemic colitis, and bowel perforation (not a boxed warning), particularly when administered with sorbitol or in post-operative, sedated, or hypoperfused patients.

Hypokalemia and Refractory Potassium Homeostasis

Hypokalemia ( [ K + ] < 3.5 mEq/L [\text{K}^+] < 3.5\text{ mEq/L} [ K + ] < 3.5 mEq/L , severe < 2.5 mEq/L < 2.5\text{ mEq/L} < 2.5 mEq/L ) hyperpolarizes myocardial cell membranes, prolongs ventricular repolarization, and promotes automaticity and re-entrant tachyarrhythmias (ventricular tachycardia, ventricular fibrillation, Torsades de Pointes).

  • Electrocardiographic Findings
  • Progressive ST-segment depression;
  • T wave flattening or inversion;
  • Prominent U waves (positive deflections immediately following the T wave, best seen in leads V2-V4);
  • Apparent QT interval prolongation (actually representing QU interval prolongation );

Atrial and ventricular premature contractions, supraventricular tachycardias, and lethal ventricular arrhythmias.

Repletion Protocols and Infusion Safety Limits

Every 1.0 mEq/L 1.0\text{ mEq/L} 1.0 mEq/L drop in serum potassium below 4.0 mEq/L 4.0\text{ mEq/L} 4.0 mEq/L corresponds to a total body potassium deficit of approximately 200 to 400 mEq 200\text{ to }400\text{ mEq} 200 to 400 mEq .

Peripheral IV Infusion Limit : Maximum rate is 10 mEq/h 10\text{ mEq/h} 10 mEq/h (concentration ≤ 40 mEq/L \le 40\text{ mEq/L} ≤ 40 mEq/L ) to prevent severe peripheral venous burning, chemical phlebitis, and sclerosis.

Central Venous Infusion Limit : In urgent ICU settings with continuous cardiac rhythm monitoring, infusions of 20 mEq/h 20\text{ mEq/h} 20 mEq/h (concentrations up to 20 − 40 mEq / 100 mL 20-40\text{ mEq}/100\text{ mL} 20 − 40 mEq /100 mL ) may be delivered via a dedicated central venous line.

The Critical Role of Magnesium in Refractory Hypokalemia

A frequent clinical failure in the ICU is refractory hypokalemia that fails to correct despite aggressive intravenous potassium repletion. The underlying cause is unrecognized concurrent hypomagnesemia .

Loading diagram...

Mechanism : The Renal Outer Medullary Potassium (ROMK) channel in the apical membrane of the cortical collecting duct secretes potassium into the tubular lumen. Intracellular magnesium ions ( M g 2 + Mg^{2+} M g 2 + ) physically bind and occlude the pore of the ROMK channel from the cytoplasmic side, acting as a molecular brake on potassium secretion (inward rectification). In hypomagnesemia, this intracellular blockade is lost, resulting in uninhibited, continuous potassium leakage into the tubular lumen.

Clinical Action : Whenever managing hypokalemia in the ICU, always measure and aggressively replete magnesium. Intravenous Magnesium Sulfate 2 g 2\text{ g} 2 g IV over 30 to 60 minutes must be co-administered to restore ROMK channel inhibition and allow successful potassium retention.

  • Hypercalcemia Crisis and Acute Hypocalcemia
  • Calcium Physiology and Protein Binding

Only the free, ionized calcium fraction ( 1.15 to 1.33 mmol/L 1.15\text{ to }1.33\text{ mmol/L} 1.15 to 1.33 mmol/L ) is biologically active. Approximately 40-45% of total serum calcium is bound to albumin. In critically ill patients with severe hypoalbuminemia, total serum calcium is falsely depressed, necessitating calculation of corrected calcium or direct ionized calcium measurement:

Corrected Total Calcium (mg/dL) = Measured Calcium (mg/dL) + 0.8 × ( 4.0 − Albumin [g/dL] ) \text{Corrected Total Calcium (mg/dL)} = \text{Measured Calcium (mg/dL)} + 0.8 \times (4.0 - \text{Albumin [g/dL]}) Corrected Total Calcium (mg/dL) = Measured Calcium (mg/dL) + 0.8 × ( 4.0 − Albumin [g/dL] )

Hypercalcemic Crisis (Total Ca > 14 mg/dL \text{Ca} > 14\text{ mg/dL} Ca > 14 mg/dL , i.e., > 3.5 mmol/L > 3.5\text{ mmol/L} > 3.5 mmol/L )

Hypercalcemia in the ICU is driven primarily by Hypercalcemia of Malignancy (80% mediated by Parathyroid Hormone-Related Protein [PTHrP] in solid tumors; 20% by osteolytic bone metastases or 1 , 25 ( OH ) 2 D 1,25(\text{OH})_2\text{D} 1 , 25 ( OH ) 2 ​ D production in lymphoma) or Primary Hyperparathyroidism .

Clinical Manifestations : Mental status depression, stupor, coma, muscle weakness, polyuria (via nephrogenic DI), nephrocalcinosis, acute kidney injury, pancreatitis, and shortened QT interval predisposing to ventricular arrhythmias.

Treatment Protocol :

Volume Resuscitation (Hour 0-24) : Infuse 0.9 % 0.9\% 0.9% Normal Saline at 200 to 300 mL/h 200\text{ to }300\text{ mL/h} 200 to 300 mL/h (titrated to restore intravascular volume and maintain urine output at 100 − 150 mL/h 100-150\text{ mL/h} 100 − 150 mL/h ). Saline expands intravascular volume, enhances glomerular filtration of calcium, and increases proximal tubular sodium delivery, which inhibits passive paracellular calcium reabsorption.

Tip

Loop diuretics (furosemide) should never be administered routinely in hypercalcemia until the patient is completely volume replete. Premature loop diuretic administration worsens volume depletion, reduces GFR, and paradoxically elevates serum calcium.

Calcitonin (Rapid Onset Bridge) : Administer Salmon Calcitonin 4 Units/kg 4\text{ Units/kg} 4 Units/kg SQ or IM every 12 hours . Calcitonin inhibits osteoclast bone resorption and promotes renal calcium clearance within 2 to 4 hours, lowering serum calcium by 1 to 2 mg/dL 1\text{ to }2\text{ mg/dL} 1 to 2 mg/dL . However, its clinical utility is limited by tachyphylaxis (downregulation of calcitonin receptors) within 24 to 48 hours.

Bisphosphonates (Definitive Long-Acting Therapy) : Administer Zoledronic Acid 4 mg 4\text{ mg} 4 mg IV over 15 minutes (or pamidronate 60 − 90 mg 60-90\text{ mg} 60 − 90 mg IV over 2-4 hours). Bisphosphonates induce osteoclast apoptosis. Onset is delayed ( 48 to 72 hours 48\text{ to }72\text{ hours} 48 to 72 hours ), with peak nadir at 4 to 7 days. Caution : Zoledronic acid carries nephrotoxic potential and requires dose adjustment or caution in severe renal impairment (eGFR < 30 mL/min < 30\text{ mL/min} < 30 mL/min ).

Denosumab (RANKL Monoclonal Antibody) : Administer Denosumab 120 mg 120\text{ mg} 120 mg SQ (with additional doses on days 8 and 15 in refractory cases). Denosumab blocks the receptor activator of nuclear factor-kappa B ligand (RANKL), halting osteoclast maturation and survival. It is the treatment of choice for severe hypercalcemia of malignancy in patients with severe renal failure where bisphosphonates are contraindicated.

Glucocorticoids : Hydrocortisone 100 mg 100\text{ mg} 100 mg IV every 8 hours (or prednisone 60 mg 60\text{ mg} 60 mg PO) is indicated specifically for hypercalcemia mediated by elevated calcitriol ( 1 , 25 ( OH ) 2 D 1,25(\text{OH})_2\text{D} 1 , 25 ( OH ) 2 ​ D ), seen in granulomatous diseases (sarcoidosis, berylliosis, tuberculosis) and certain lymphomas.

Hemodialysis : Emergent hemodialysis against a low-calcium or zero-calcium dialysate is reserved for patients with severe hypercalcemic crisis ( > 18 mg/dL > 18\text{ mg/dL} > 18 mg/dL ), refractory neurological collapse, or concurrent anuric renal failure or heart failure that precludes saline hydration.

Acute Hypocalcemia (Ionized Ca < 0.9 mmol/L \text{Ca} < 0.9\text{ mmol/L} Ca < 0.9 mmol/L )

Etiologies : Massive blood transfusion (citrate anticoagulation binds ionized calcium), post-parathyroidectomy ("hungry bone syndrome"), severe acute pancreatitis (saponification of mesenteric fat), severe sepsis, severe hypomagnesemia.

Clinical Manifestations : Neuromuscular irritability, perioral and fingertip paresthesias, painful carpopedal spasms, Chvostek's sign (facial twitching upon tapping the facial nerve anterior to the ear), Trousseau's sign (carpal spasm induced by inflating a sphygmomanometer cuff above systolic blood pressure for 3 minutes), and QT interval prolongation (due to lengthening of Phase 2 ST segment), predisposing to Torsades de Pointes.

Treatment : In acute symptomatic hypocalcemia, administer 1 to 2 g 1\text{ to }2\text{ g} 1 to 2 g of Calcium Gluconate IV in 50 to 100 mL 50\text{ to }100\text{ mL} 50 to 100 mL D5W over 10 to 20 minutes 10\text{ to }20\text{ minutes} 10 to 20 minutes , followed by a continuous infusion of elemental calcium at 1 to 2 mg/kg/h 1\text{ to }2\text{ mg/kg/h} 1 to 2 mg/kg/h . Concurrently check and correct serum magnesium.

Severe Hypophosphatemia and Refeeding Syndrome

Phosphate is essential for cellular bioenergetics (ATP generation), structural cell membrane integrity (phospholipids), and tissue oxygen unloading (2,3-diphosphoglycerate [2,3-DPG]). Severe hypophosphatemia is defined as serum phosphate < 1.0 mg/dL < 1.0\text{ mg/dL} < 1.0 mg/dL ( < 0.32 mmol/L < 0.32\text{ mmol/L} < 0.32 mmol/L ) .

Clinical Manifestations of ATP and 2,3-DPG Depletion

Pulmonary : Diaphragmatic contractile failure, respiratory muscle fatigue, and inability to liberate (wean) from mechanical ventilation ;

Cardiovascular : Impaired myocardial contractility, acute heart failure, decreased stroke volume, and ventricular dysrhythmias;

Neurological : Metabolic encephalopathy, delirium, seizures, paresthesias, ascending motor paralysis mimicking Guillain-Barré syndrome;

Hematologic & Muscular : Acute rhabdomyolysis, impaired erythrocyte membrane deformability leading to hemolytic anemia, and leukocyte dysfunction.

Refeeding Syndrome

Occurs when malnourished, starved, or chronically alcoholic patients receive aggressive enteral or parenteral nutrition:

Chronic starvation depletes whole-body phosphate, potassium, magnesium, and thiamine, although serum levels may appear falsely normal due to hemoconcentration and intracellular shifts.

Carbohydrate administration stimulates a massive surge in endogenous insulin secretion .

Insulin triggers rapid intracellular uptake of glucose, phosphate, potassium, and magnesium, while simultaneously activating cellular glycolysis and glycogen synthesis.

Acute, severe depletion of extracellular phosphate, potassium, and magnesium follows within 24 to 72 hours, precipitating fatal cardiac arrhythmias, acute cardiogenic pulmonary edema, and sudden arrest.

Prevention & Protocol : Before initiating nutrition in high-risk patients, measure baseline electrolytes; administer prophylactic thiamine ( 100 − 200 mg 100-200\text{ mg} 100 − 200 mg IV) ; start caloric intake at a conservative 10 − 15 kcal/kg/day 10-15\text{ kcal/kg/day} 10 − 15 kcal/kg/day ; and proactively replete phosphate ( > 2.5 mg/dL > 2.5\text{ mg/dL} > 2.5 mg/dL ), potassium ( > 4.0 mEq/L > 4.0\text{ mEq/L} > 4.0 mEq/L ), and magnesium ( > 2.0 mg/dL > 2.0\text{ mg/dL} > 2.0 mg/dL ).

Intravenous Phosphate Repletion Protocol

Severe hypophosphatemia ( < 1.0 mg/dL < 1.0\text{ mg/dL} < 1.0 mg/dL ): Administer 0.24 to 0.48 mmol/kg 0.24\text{ to }0.48\text{ mmol/kg} 0.24 to 0.48 mmol/kg of IV Sodium Phosphate or Potassium Phosphate infused over 4 to 6 hours 4\text{ to }6\text{ hours} 4 to 6 hours (maximum infusion rate 7 mmol/h 7\text{ mmol/h} 7 mmol/h ).

Select potassium phosphate if concurrent hypokalemia exists; select sodium phosphate if serum potassium is normal or elevated.

Tumor Lysis Syndrome (TLS): Cairo-Bishop Criteria and ICU Protocol

Tumor Lysis Syndrome represents the massive, acute release of intracellular contents following the destruction of rapidly proliferating, chemosensitive malignant cells (typically high-grade hematologic malignancies: Burkitt lymphoma, acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML], or bulky diffuse large B-cell lymphoma).

Loading diagram...

  • Cairo-Bishop Diagnostic Definitions
  • 1. Laboratory TLS (LTLS)

Established when two or more of the following metabolic disturbances occur simultaneously within 3 days before or 7 days after the initiation of cytotoxic chemotherapy:

Hyperuricemia : Serum uric acid ≥ 8.0 mg/dL \ge 8.0\text{ mg/dL} ≥ 8.0 mg/dL (or 25 % 25\% 25% increase from baseline);

Hyperkalemia : Serum potassium ≥ 6.0 mEq/L \ge 6.0\text{ mEq/L} ≥ 6.0 mEq/L (or 25 % 25\% 25% increase from baseline);

Hyperphosphatemia : Serum phosphorus ≥ 4.5 mg/dL \ge 4.5\text{ mg/dL} ≥ 4.5 mg/dL (or 25 % 25\% 25% increase from baseline);

Hypocalcemia : Serum total calcium ≤ 7.0 mg/dL \le 7.0\text{ mg/dL} ≤ 7.0 mg/dL or ionized calcium < 1.12 mmol/L < 1.12\text{ mmol/L} < 1.12 mmol/L (or 25 % 25\% 25% decrease from baseline).

2. Clinical TLS (CTLS)

Established when Laboratory TLS is present accompanied by at least one of the following clinical complications:

  • Acute kidney injury (serum creatinine ≥ 1.5 × \ge 1.5\times ≥ 1.5 × upper limit of normal or baseline);
  • Cardiac arrhythmia or sudden cardiac death;

Generalized seizures, tetany, or neuromuscular irritability.

Comprehensive Management Protocol in the ICU

Aggressive Isotonic Crystalloid Hydration :

Administer balanced crystalloids or 0.9 % 0.9\% 0.9% saline at 2 to 3 L/m 2 / day 2\text{ to }3\text{ L/m}^2/\text{day} 2 to 3 L/m 2 / day (or 150 to 200 mL/h 150\text{ to }200\text{ mL/h} 150 to 200 mL/h ) to maintain high tubular flow and dilute intraluminal solute concentration.

Resuscitation target: Urine output > 100 mL/m 2 / h > 100\text{ mL/m}^2/\text{h} > 100 mL/m 2 / h (approximately > 2 mL/kg/h > 2\text{ mL/kg/h} > 2 mL/kg/h ). Add loop diuretics (furosemide) only if urine output fails to match high fluid intake after adequate volume repletion.

Note on Urinary Alkalinization : Historically, sodium bicarbonate infusions were used to alkalinize urine (target urine pH > 7.0 \text{pH} > 7.0 pH > 7.0 ) to increase uric acid solubility. Urinary alkalinization is no longer recommended : while it solubilizes uric acid, alkaline urine markedly decreases calcium-phosphate solubility, promoting fatal metastatic calcium phosphate precipitation in renal tubules and myocardium.

Uric Acid Lowering Therapy :

Rasburicase (Recombinant Urate Oxidase) : Directly converts insoluble uric acid into allantoin , an inert, highly water-soluble metabolite readily excreted by the kidneys (solubility is 10 × 10\times 10 × higher than uric acid). Dose: 0.15 to 0.2 mg/kg 0.15\text{ to }0.2\text{ mg/kg} 0.15 to 0.2 mg/kg IV over 30 minutes (or a single fixed dose of 3 to 6 mg 3\text{ to }6\text{ mg} 3 to 6 mg IV in non-extreme cases). It drops serum uric acid levels within 4 hours.

Warning

Rasburicase Contraindication : Strictly contraindicated in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency . Urate oxidase generates hydrogen peroxide ( H 2 O 2 H_2O_2 H 2 ​ O 2 ​ ) during the enzymatic breakdown of uric acid. In G6PD-deficient erythrocytes that lack glutathione antioxidant capacity, H 2 O 2 H_2O_2 H 2 ​ O 2 ​ induces severe methemoglobinemia and acute intravascular hemolytic anemia .

Allopurinol : A competitive xanthine oxidase inhibitor ( 300 mg/day 300\text{ mg/day} 300 mg/day PO or 200 − 400 mg/m 2 / day 200-400\text{ mg/m}^2/\text{day} 200 − 400 mg/m 2 / day IV). Allopurinol blocks the formation of new uric acid from hypoxanthine and xanthine, but does not degrade pre-existing uric acid crystals. It is used for low/intermediate-risk prophylaxis, not for acute established severe hyperuricemia.

Strict Calcium Management Rule in TLS :

In Tumor Lysis Syndrome, the calcium-phosphate product often exceeds 60 to 70 mg 2 / dL 2 60\text{ to }70\text{ mg}^2/\text{dL}^2 60 to 70 mg 2 / dL 2 .

Do NOT administer intravenous calcium to correct asymptomatic hypocalcemia in TLS! Exogenous calcium combines with excess circulating phosphate, driving precipitous systemic calcium phosphate crystal precipitation in the renal tubulointerstitium, cardiac conduction tissue, and pulmonary capillaries, rapidly exacerbating acute tubular necrosis and inducing fatal arrhythmias.

Intravenous calcium gluconate is indicated only if the patient develops life-threatening manifestations of hypocalcemia: tetany, generalized seizures, or documented ECG evidence of severe conduction block or refractory QTc prolongation.

  • Potassium Pitfalls: Pseudohyperkalemia, Drug Causes and Hypokalemia Workup
  • Pseudohyperkalemia

A high potassium result with a normal ECG should prompt a search for pseudohyperkalemia , where potassium leaves cells in the tube rather than in the patient:

Hemolysis from a difficult draw, small needles, or vigorous shaking.

Repeated fist clenching and prolonged tourniquet time.

Marked thrombocytosis (often above about 500,000 / μ L 500{,}000/\mu\text{L} 500 , 000/ μ L ) or leukocytosis (for example, chronic lymphocytic leukemia with very high counts), because cells release potassium as the sample clots.

Confirm with a heparinized plasma sample or a whole-blood potassium on the blood gas analyzer, run promptly without pneumatic-tube transport. Do not give potassium-lowering therapy for a result that the clinical picture does not support.

Drug-Induced and Endocrine Hyperkalemia

Mechanism Examples

Reduced aldosterone production or effect ACE inhibitors, ARBs, direct renin inhibitors, heparin (including prophylactic doses), NSAIDs, calcineurin inhibitors (tacrolimus, cyclosporine)

  • Mineralocorticoid receptor blockade Spironolactone, eplerenone, finerenone
  • ENaC blockade in the collecting duct Trimethoprim, pentamidine, amiloride, triamterene

Impaired cellular uptake Nonselective beta-blockers, digoxin toxicity (Na/K-ATPase inhibition), insulin deficiency, hypertonicity

Depolarizing release Succinylcholine in burns, crush injury, denervation, or prolonged immobilization (upregulated extrajunctional receptors)

Endocrine Primary adrenal insufficiency (with hyponatremia), hyporeninemic hypoaldosteronism (diabetic kidney disease)

Hypokalemia: Where Is the Potassium Going?

Transcellular shift : insulin, beta-2 agonists, alkalemia, refeeding, hypothermia, thyrotoxic or familial periodic paralysis, and barium or chloroquine toxicity. Total body potassium is normal, so replacement can cause rebound hyperkalemia.

Vomiting or nasogastric suction : gastric fluid holds little potassium. The loss is mainly renal : metabolic alkalosis delivers bicarbonate to the collecting duct, and volume depletion activates aldosterone. The urine chloride is low (below about 20 mEq/L 20\text{ mEq/L} 20 mEq/L ) even when urine sodium is not.

Diarrhea : direct gastrointestinal loss with a normal anion gap metabolic acidosis .

Renal potassium wasting : a spot urine potassium-to-creatinine ratio above about 13 mEq/g 13\text{ mEq/g} 13 mEq/g (about 1.5 mEq/mmol 1.5\text{ mEq/mmol} 1.5 mEq/mmol ) points to renal loss: diuretics, mineralocorticoid excess, magnesium depletion, amphotericin B, renal tubular acidosis, or osmotic diuresis. A lower ratio suggests extrarenal loss or a shift.

  • Magnesium Disorders
  • Hypomagnesemia

Causes : chronic proton-pump inhibitor use, loop and thiazide diuretics, alcohol use disorder, diarrhea and malabsorption, refeeding, and nephrotoxic drugs (aminoglycosides, amphotericin B, cisplatin, foscarnet, pentamidine, calcineurin inhibitors, EGFR antibodies such as cetuximab).

Consequences : refractory hypokalemia (loss of magnesium's block of ROMK channels), hypocalcemia (impaired PTH secretion and PTH resistance), tremor, tetany, seizures, QT prolongation, torsades de pointes, and atrial fibrillation.

Treatment : give 1 – 2 g 1\text{--}2\text{ g} 1 – 2 g IV magnesium sulfate for symptomatic deficiency, over about 5 to 15 minutes in torsades with a pulse (faster only in pulseless arrest), then a slower infusion because much of a rapid bolus is excreted. Reduce doses in kidney failure.

Hypermagnesemia

Hypermagnesemia is almost always iatrogenic with reduced kidney function : magnesium sulfate infusions for preeclampsia, magnesium-containing laxatives, enemas, or antacids.

Approximate serum magnesium Typical findings

4 – 6 mEq/L 4\text{--}6\text{ mEq/L} 4 – 6 mEq/L (about 4.8 – 7.2 mg/dL 4.8\text{--}7.2\text{ mg/dL} 4.8 – 7.2 mg/dL ) Nausea, flushing, lethargy, loss of deep tendon reflexes (the bedside warning sign during obstetric infusions)

6 – 10 mEq/L 6\text{--}10\text{ mEq/L} 6 – 10 mEq/L Hypotension, bradycardia, somnolence, prolonged PR and QRS intervals

Above about 10 mEq/L 10\text{ mEq/L} 10 mEq/L (about 12 mg/dL 12\text{ mg/dL} 12 mg/dL ) Respiratory paralysis, complete heart block, cardiac arrest

Treatment : stop all magnesium; give IV calcium (calcium gluconate 1 – 2 g 1\text{--}2\text{ g} 1 – 2 g ) to antagonize the membrane effects; give isotonic fluid with a loop diuretic if kidney function allows; and use hemodialysis for severe toxicity with kidney failure. Support ventilation if reflexes and respiratory effort are lost.